Ponezumab (PF-04360365, RN 1219) is a humanized anti-amyloid-beta (Amyloid-beta) IgG2 monoclonal antibody. Ponezumab reduces Abeta levels in the central nervous system and improves the performance of mice in various learning and memory models. Ponezumab is applicable to the research of Alzheimers disease[1].
Molecular Weight:
(145.65 kDa)
Purity:
97.89
CAS Number:
[1178862-65-1]
Target:
Amyloid-beta
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted